2026
RVPH Reviva Pharmaceuticals Holdings, Inc.
TPR Tapestry Inc
BGRY Berkshire Grey Inc
BKNG Booking Holdings Inc
UHT Universal Health Realty Income Trust
BBVA Banco Bilbao Vizcaya Argentaria SA
RILY B Riley Financial Inc
WTS Watts Water Technologies Inc
Go

Health Care : Pharmaceuticals | Small Cap Value

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. It also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.

Closing Price: $0.048

Day's Change: -0.001 (-2.04%)

Bid: --

Ask: --

B/A Size: --

Day's High: 0.05

Day's Low: 0.0471

Volume (Light) Volume: 1,923,446 10-day average volume: 3,536,102: 1,923,446

Annual Earnings Missed Consensus (Year ending 12/2021)						Next Earnings Announcement
Annual Non-GAAP earnings GAAP vs. Non-GAAP Earnings TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced March 3, 2022	-$23.70	Annual Consensus of 4 analysts	-$21.60	Difference from consensus	-9.72%	2022 Earnings will announce	(Unconfirmed) March 2, 2023

Annual Earnings History and Estimates

Show high-low estimates

EVFM's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

GAAP vs. Non-GAAP Earnings

Annual Earnings History and Estimates